Donate

Industry News

BAXTER: PHASE I TRIAL OF LONGER-ACTING RECOMBINANT FVIII

January 5, 2012

Link to Baxter’s Press Release BAXTER INITIATES PHASE I CLINICAL TRIAL OF LONGER-ACTING RECOMBINANT FVIII TREATMENT FOR HEMOPHILIA A Investigational BAX 855 is based on ADVATE Factor VIII Molecule DEERFIELD, Ill., January 5, 2012 – Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead […]

FDA Approves Baxter’s ADVATE as the Only FVIII for Routine Prophylaxis

December 19, 2011

Direct link to Press Release ADVATE for routine prophylaxis reduced annual bleed events in hemophilia A patients from forty-four to one as compared to an on-demand regimen in a clinical study Once every third day pharmacokinetic dosing option offers some patients the opportunity for fewer infusions annually DEERFIELD, Ill., December 16, 2011 – Baxter International […]

Baxter: Labeling Error on Sterile Water

November 17, 2011

Link to NHF’s Medical Advisory November 16, 2011 Baxter Healthcare Corporation has sent a notice of a labeling error affecting the expiration date of the Sterile Water for Injection that is packaged as a diluent with RECOMBINATE [Antihemophilic Factor (Recombinant)]. The Sterile Water for Injection label indicates that the shelf life is longer than what […]

Chinese Firms Linked to Tainted Heparin Still Supplying U.S.

October 28, 2011

By Anna Edney Courtesy of Bloomberg News Oct. 26 (Bloomberg) — Two Chinese companies implicated in supplying contaminated ingredients three years ago to Baxter International Inc. for its blood thinner heparin are still supplying product to the U.S., Republican lawmakers said. Baxter recalled the blood thinner in 2008 amid reports of deaths and allergic reactions. […]

Baxter: Phase III trial of Von Willebrand Treatment

October 14, 2011

FOR IMMEDIATE RELEASE Media Contacts: Deborah Spak, (847) 948-2349 Marie Kennedy, (805) 372-3543 Investor Contacts: Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085 BAXTER INITIATES PHASE III TRIAL OF INVESTIGATIONAL BAX 111 FOR THE TREATMENT OF VON WILLEBRAND DISEASE First Recombinant Product in Clinical Development for Most Common Inherited Bleeding Disorder DEERFIELD, Ill., OCTOBER […]

Drug Companies May Face Uphill Battle on Passage of FDA Review Funding

September 5, 2011

CQ TODAY ONLINE NEWS – HEALTH Sept. 2, 2011 – 8:17 p.m. By Emily Ethridge, CQ Staff The pharmaceutical industry continues to push lawmakers to act quickly on approving a deal that would fund the Food and Drug Administration’s drug review process. But, although lawmakers from both parties have pledged to mark up the legislation […]

NEWS/UPDATE: BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM PRESENT DATA ON LONG-LASTING RECOMBINANT FACTOR VIII THERAPY AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS MEETING

August 10, 2011

Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Recombinant Factor VIII Therapy at International Society on Thrombosis and Haemostasis Meeting —Results Show Potential to Significantly Reduce the Burden of Treatment for People with Hemophilia A— KYOTO, Japan, Jul 26, 2011 (BUSINESS WIRE) — Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) […]

Blood test can identify fetal sex as early as 7 weeks gestation

August 9, 2011

August 9, 2011 Fetal sex can be determined reliably with a non-invasive genetic test as early as 7 weeks into a pregnancy, according to a new meta-analysis published this week in the Journal of the American Medical Association. The results of the NIH-funded analysis have important implications for early diagnosis of genetic diseases linked to […]

CSL Behring Donates von Willebrand Factor / Factor VIII Donation to World Federation of Hemophilia

August 5, 2011

Company gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization King of Prussia, PA – July 18, 2011 – CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication […]

BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM

August 5, 2011

KYOTO, Japan – July 26, 2011 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM present data On LONG-LASTING RECOMBINANT factor VIII therapy at international society on thrombosis and haemostasis meeting —Results Show Potential to Significantly Reduce the Burden of Treatment for People with Hemophilia A— Biogen Idec聽(NASDAQ: BIIB) and聽Swedish Orphan Biovitrum聽(STO: SOBI) today announced Phase 1/2a trial […]

Baxter Voluntary Recall

July 28, 2011

Notice: Baxter is voluntarily recalling one (1) lot of RECOMBINATE [Antihemophilic Factor (Recombinant)], product code 1501594, NDC Number 0944-2833-10, lot number TRA09834AB, with an expiry date of January 28, 2012. This action is being taken as a precautionary measure after a retrospective review of manufacturing processes revealed a potential breach in aseptic processing may have […]

BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR

July 26, 2011

FOR IMMEDIATE RELEASE Media Contacts Doreen Eaton, (805) 372-3417 Marie Kennedy, (805) 372-3543 Investor Contacts Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085 BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR Three Baxter Scientists Granted […]

CSL Behring Donates von Willebrand Factor / Factor VIII Donation to World Federation of Hemophilia

July 21, 2011

Link to news release Company gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization King of Prussia, PA 鈥 18 July 2011 CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII […]

KOGENATE庐 FS, ANTIHEMOPHILIC FACTOR (RECOMBINANT), FOR HEMOPHILIA A NOW EASIER FOR PEOPLE TO STORE AT HOME OR ON THE GO

June 13, 2011

Click for link to article WAYNE, NJ, April 25, 2011 – Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved a new storage option for Kogenate® FS, antihemophilic factor (recombinant), now allowing the product to be stored at room temperature (up to 77掳 F) for up to one year. […]

BioRx Is Fast 55 Award Finalist

April 25, 2011

News Release 聽(Cincinnati, Ohio)聽 April 25, 2011聽聽 The Cincinnati Business Courier announces that BioRx is again a finalist, for the third consecutive year, in its Fast 55 Award Program.聽 Currently listed in the $50.1 to $199 million category, BioRx also won a Fast 55 Award in 2008 and 2009.聽 The Business Courier moved the 2010 […]

Novo Nordisk Annals Letter to the Editor

April 19, 2011

Novo Nordisk Annals Letter to the Editor

Biogen Idec Celebrates World Hemophilia Day

April 19, 2011

April 15, 2011 Dear members of the bleeding disorders community, On Sunday, alongside individuals with bleeding disorders and their families, advocates and healthcare professionals, Biogen Idec celebrates World Hemophilia Day and reinforces our strong commitment to scientific discovery focused on changing the lives of people with hemophilia. While hemophilia is a new disease area for […]

Drug That Slows Bleeding Shows Off-Label Dangers

April 19, 2011

Link to New your Times Article By GINA KOLATA Published: April 18, 2011 A powerful, costly drug approved in 1999 for a small group of patients who may bleed uncontrollably during surgery is now used in a host of other surgical situations, sometimes with serious negative effects, two new studies report. The studies present a […]

H&P Industries, Inc. Issues a Voluntary Nationwide Recall of All Lots of POVIDINE PREP PADS

March 21, 2011

Contact: Customer Service 262-538-2900 FOR IMMEDIATE RELEASE 鈥 March 15, 2011 鈥擧artland, Wisconsin, H&P industries, Inc.,聽a manufacturer of over-the-counter products has initiated a voluntary product recall of ALL LOTS of POVIDINE PREP PADS manufactured by H&P Industries, Inc. but which are private labeled for many accounts.聽This recall has been initiated due to results of the […]

Grifols Alphanate vCJD Labeling Press Release

March 4, 2011

FOR IMMEDIATE RELEASE FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD Alphanate® is the first plasma-derived blood clotting factor to include labeling statements on manufacturing processes that provide a reasonable assurance of removal for low levels of a variant Creutzfeldt-Jakob disease (vCJD) model agent. Barcelona, Spain (March […]

Bayer Hemophilia Leadership Development Program

February 3, 2011

Apply for the Bayer Hemophilia Leadership Development Program today. It’s your chance to participate in a summer internship that will help develop the skills needed to be a successful leader. Take this opportunity to ask questions, learn from business professionals, develop key relationships, prepare for real-world transitions after college, and more importantly, have FUN! Deadline […]

Pfizer Inc. And Progenics Alert Physicians And Patients To Information Related To Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging Wed, 26 Jan 2011 10:53:00 -0600 NEW YORK, N.Y. and TARRYTOWN, N.Y.

January 26, 2011

Pfizer Inc. and Progenics Pharmaceuticals, Inc. have learned of a United States market recall of alcohol prep pads and swabs manufactured by the Triad Group. In the interest of patient safety, Pfizer and Progenics are alerting U.S. patients and physicians to Triad’s recall.

News Release BioRx Announces New Chief Financial Officer

January 10, 2011

January 10, 2011 (Cincinnati, Ohio)聽 BioRx announced it has hired Robin R. Johnson, MBA, CPA, as its new Chief Financial Officer. Johnson comes to BioRx from Vohra Health Services of Miami, Florida, the nation’s largest wound care provider, where she served as Interim Chief Financial Officer. At BioRx, Johnson’s responsibilities are to plan, implement, and […]

Important Information for the Hemophilia Community Regarding Triad Group’s Alcohol Prep Products and Bayer’s BayCuffTM and First Aid Kit

January 10, 2011

Click here to letter from Bayer January 10, 2011 Dear Bayer Customer: Bayer HealthCare Pharmaceuticals has become aware of a broad United States market recall of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. In the interest of patient safety, Bayer wants to ensure that you […]

RECALL: Triad Group Issues a Voluntary Nationwide Recall of All Lots of Alcohol Prep Pads, Alcohol Swabs, and Alcohol Swabsticks Due to Potential Microbial Contamination

January 7, 2011

Article Link Contact: Eric Haertle, COO 262-538-2900 FOR IMMEDIATE RELEASE – January 5, 2011 – Hartland, Wisconsin, Triad Group, a manufacturer of over-the-counter products has initiated a voluntary product recall involving ALL LOTS of ALCOHOL PREP PADS, ALCOHOL SWABS, and ALCOHOL SWABSTICKS manufactured by Triad Group but which are private labeled for many accounts to […]

Biogen Idec Press Release: Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein

December 7, 2010

Click here for press release First Long-Lasting Factor VIII Candidate in Late-Stage Clinical Trial for Treatment of Hemophilia A WESTON, Mass. & STOCKHOLM, Dec 06, 2010 (BUSINESS WIRE) — Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) today announced that the first patient has been dosed with the companies’ long-lasting recombinant Factor VIII […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.